Clinical trials: Nab-paclitaxel
Healthy
A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers
The purpose of Part 1 of this First-in-Human trial is to evaluate the safety and tolerability after single ascending oral doses of IOA-289 given to healthy male subjects, compared to placebo.
- Trial name
- NCT05027568
- Testing
- IOA-289, Nab paclitaxel / gemcitabine
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- iOnctura
Liver Cancer, Pancreatic Cancer
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
The study consists in a co-clinical trial by using zebrafish embryos. Specifically, an observational prospective clinical trial on patients operated of epato-biliar-pancreatic cancers and gastro-intestinal cancers undergoing a…
- Conditions
- Liver Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- xenoZ (NCT03668418)
- Testing
- Fluorouracil, Lederfolin, Oxaliplatin
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Metastatic Pancreatic Cancer
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
This is a single arm, open-label Phase II clinical trial to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients with metastatic pancreatic cancer.
- Trial name
- NCT03929094
- Testing
- Paclitaxel for Injection（Albumin Bound）, Gemcitabine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fudan University
Pancreatic Adenocarcinoma Metastatic
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
This is a multi-center, open-label， randomized controlled Phase II clinical study to observe and evaluate the efficacy and safety of Penpulimab combined with Anlotinib and Nab-paclitaxel plus Gemcitabine (PAAG ) versus AG…
- Trial name
- RCT-PAAG (NCT06051851)
- Testing
- Penpulimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return.
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
- Trial name
- NCT04585477
- Testing
- AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Stanford University
Breast Cancer, Peripheral Neuropathy
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.
- Trial name
- NCT04675450
- Testing
- NBP Softgel Capsules
- Volunteers
- healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Breast Cancer
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
This is a phase II, explorative, open-labeled, multi-centered, double-arm, investigator-initiated clinical trial of Camrelizumab (an anti-PD-1 antibody) in combination with Nab-paclitaxel (a chemotherapeutic agent against breast…
- Trial name
- NCT06632405
- Testing
- Camrelizumab, Nab paclitaxel, Levocetirizine Hydrochloride
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University